EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Stimuli‐Responsive Hydrogels for Cancer Therapy: Design Strategies, Mechanisms, and Challenges in Clinical Translation

Negar Paknia, Hadis Soltanimehr, Hadieh Rahbar Kafshboran, Soheila Ghasemi

ChemMedChem · 2026-11-12 · 21 (21)

DOI: 10.1002/cmdc.70552 ↗
AstrattDettalji biblijografiċi

Astratt

Stimuli‐responsive hydrogels (SRHs) are versatile soft biomaterials capable of dynamically responding to environmental cues, enabling controlled and site‐specific drug release for cancer therapy. Advances in polymer chemistry and nanotechnology have facilitated the development of SRHs that respond to tumor‐associated stimuli, including pH, redox potential, temperature, enzymatic activity, light, and glucose gradients. Among these systems, pH‐ and redox‐responsive hydrogels exploit the acidic and oxidative tumor microenvironment, while thermo‐ and photo‐responsive platforms enable spatiotemporal regulation of therapeutic payloads. Recent studies have demonstrated highly efficient, stimulus‐triggered drug release and enhanced therapeutic outcomes in vitro and in vivo. This review systematically examines the design strategies, molecular mechanisms, and structure–function relationships governing SRHs in oncology. Emerging hydrogel architectures—such as injectable systems, hybrid nanocomposites, and multifunctional platforms integrating targeting or imaging capabilities—are critically discussed. Importantly, the review addresses key challenges in clinical translation, including biocompatibility, scalability, regulatory considerations, and reproducibility. Finally, future perspectives are outlined, highlighting the potential of artificial intelligence‐assisted material design, computational modeling, and wearable or implantable bioelectronic interfaces for real‐time monitoring and adaptive cancer therapy. By integrating mechanistic insights with translational and regulatory viewpoints, this review aims to guide the rational development of next‐generation smart hydrogel therapeutics for clinical oncology.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →